健康元: 健康元药业集团股份有限公司监事会关于本公司九届监事会九次会议相关议案之审核意见

Group 1 - The Supervisory Board of the company reviewed the 2025 semi-annual report and its summary, concluding that the preparation and review procedures comply with relevant laws, regulations, and internal management systems [2] - The content and format of the semi-annual report and its summary meet the requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange, accurately reflecting the company's operational management and financial status for the first half of 2025 [2] - The Supervisory Board confirmed that the personnel involved in the preparation and review of the semi-annual report did not violate confidentiality regulations [2] Group 2 - The Supervisory Board conducted a special report review on the management and actual use of raised funds for the first half of 2025, finding that the management and use of raised funds comply with regulatory requirements and the company's fundraising management system [2] - The use of raised funds was deemed legal and compliant, with no violations of laws or regulations that could harm shareholder interests identified [2]